Palivizumab for the prevention of respiratory syncytial virus infection

Article Figures & Data

Table 1.

Indications for administering palivizumab for RSV prophylaxis

PALIVIZUMAB USE	CRITERIA
Routine	Children younger than 2 years of age with CLD due to prematurity who require ongoing medical therapy (oxygen, steroids, or daily bronchodilator therapy) within the 6 months preceding the RSV season
	Children younger than 2 years of age with hemodynamically significant cyanotic and acyanotic heart disease
	Infants born at 32 weeks’ gestation or earlier who are 6 months of age or younger (with or without CLD) at the start of the RSV season
	Children in isolated northern or rural remote communities (eg, children who require air transportation to hospital facilities), born before 36 weeks’ gestation, if they are younger than 6 months of age at the onset of RSV season
Discretionary	Full-term Inuit infants younger than 6 months of age at the onset of the RSV season in northern remote communities (eg, children who require air transportation to hospital facilities), regardless of gestational age
	Some patients with severe CLD or congenital heart disease, who require ongoing medical therapy
	Children with severe immunodeficiency diseases and those with other rare conditions, such as Down syndrome, at high risk of developing severe disease with RSV in the first year of life